Literature DB >> 1586596

Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.

C F Molthoff1, H M Pinedo, H M Schlüper, H W Nijman, E Boven.   

Abstract

Monoclonal antibody (MAb) 139H2 was previously shown to localise specifically into ovarian cancer xenografts in nude mice. MAb 139H2 was compared with MAbs OC125 and OV-TL 3, all reactive with ovarian carcinomas, for the binding characteristics as IgG and F(ab')2 fragments with the use of the OVCAR-3 cell line grown in vitro and as s.c. xenografts. Immunoperoxidase staining of OVCAR-3 tissue sections with MAbs OC125 and 139H2 was heterogeneous, whereas MAb OV-TL 3 showed homogeneity. No differences in binding were observed between IgG and F(ab')2. The avidity expressed as apparent affinity constants of MAbs OC125, OV-TL 3 and 139H2 for OVAR-3 cells were 1 x 10(9) M-1, 1 x 10(9) M-1, and 1 x 10(8) M-1, while the number of antigenic determinants were 5 x 10(6), 1 x 10(6) and 7 x 10(6), respectively. In OVCAR-3 bearing nude mice the blood half-lives of the MAbs as IgG and F(ab')2 were approximately 50 h and 6 h, respectively. Maximum tumour uptake for the whole MAbs OC125, OV-TL 3, 139H2 and a control MAb 2C7 was 8.5%, 17.7%, 11.1% and 2.5% of the injected dose g-1, reached at 72 h after injection. For the respective F(ab')2 fragments, the maximum values were 5.2%, 10.0%, 5.5% and 1.9% of the injected dose g-1, reached between 6 h and 15 h. Tumour to non-tumour ratios were more favourable for the F(ab')2 fragments as compared to those for MAbs as IgG. Biodistribution in mice bearing a control tumour confirmed the specificity of tumour localisation of MAbs OC125, OV-TL 3 and 139H2. After injection of a tracer dose of 10 microCi of radiolabelled MAbs OC125, OV-TL 3 and 139H2 as IgG, tumours received 38 cGy, and 9 cGy. In our OVCAR-3 model, a ranking in efficiency in tumour localisation would indicate MAb OV-TL 3 as most favourable MAb, but cross-reactivity with subpopulations of human white blood cells might hamper its clinical use. Dosimetric data indicate a 4-fold higher radiation absorbed dose to tumours for IgG compared with F(ab')2 fragments.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586596      PMCID: PMC1977382          DOI: 10.1038/bjc.1992.144

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Characterization of the WIDR: a human colon carcinoma cell line.

Authors:  P Noguchi; R Wallace; J Johnson; E M Earley; S O'Brien; S Ferrone; M A Pellegrino; J Milstien; C Needy; W Browne; J Petricciani
Journal:  In Vitro       Date:  1979-06

2.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

3.  Monoclonal antibodies against human beta-glucocerebrosidase.

Authors:  R A Barneveld; F P Tegelaers; E I Ginns; P Visser; E A Laanen; R O Brady; H Galjaard; J A Barranger; A J Reuser; J M Tager
Journal:  Eur J Biochem       Date:  1983-08-15

4.  Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture.

Authors:  J Taylor-Papadimitriou; J A Peterson; J Arklie; J Burchell; R L Ceriani; W F Bodmer
Journal:  Int J Cancer       Date:  1981-07-15       Impact factor: 7.396

5.  Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice.

Authors:  F Buchegger; A Pèlegrin; B Delaloye; A Bischof-Delaloye; J P Mach
Journal:  J Nucl Med       Date:  1990-06       Impact factor: 10.057

6.  Lack of radioimmunodetection and complications associated with monoclonal anticarcinoembryonic antigen antibody cross-reactivity with an antigen on circulating cells.

Authors:  R O Dillman; J C Beauregard; R E Sobol; I Royston; R M Bartholomew; P S Hagan; S E Halpern
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

7.  Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody.

Authors:  L M Lamki; Y Z Patt; M G Rosenblum; L J Shanken; L B Thompson; S A Schweighardt; J M Frincke; J L Murray
Journal:  Radiology       Date:  1990-01       Impact factor: 11.105

8.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

Authors:  T C Hamilton; R C Young; W M McKoy; K R Grotzinger; J A Green; E W Chu; J Whang-Peng; A M Rogan; W R Green; R F Ozols
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

9.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

10.  Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice.

Authors:  F Buchegger; C M Haskell; M Schreyer; B R Scazziga; S Randin; S Carrel; J P Mach
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

2.  Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue.

Authors:  M R Buist; C F Molthoff; P Kenemans; C J Meijer
Journal:  J Clin Pathol       Date:  1995-07       Impact factor: 3.411

Review 3.  Pharmacokinetics of Monoclonal Antibodies.

Authors:  Josiah T Ryman; Bernd Meibohm
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-29

4.  Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.

Authors:  G P Adams; R Schier; A M McCall; R S Crawford; E J Wolf; L M Weiner; J D Marks
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.